Positron Emission Tomography Tracers for Imaging Angiogenesis

Overview

Journal Eur J Nucl Med Mol Imaging

Specialties Biophysics
Nuclear Medicine
Radiology

Date 2010 Jun 19

PMID 20559632

Citations 44

Authors

Roland Haubner

Ambros J Beer

Hui Wang

Xiaoyuan Chen

Affiliations

Soon will be listed here.

Abstract

Position emission tomography imaging of angiogenesis may provide non-invasive insights into the corresponding molecular processes and may be applied for individualized treatment planning of antiangiogenic therapies. At the moment, most strategies are focusing on the development of radiolabelled proteins and antibody formats targeting VEGF and its receptor or the ED-B domain of a fibronectin isoform as well as radiolabelled matrix metalloproteinase inhibitors or alpha(v)beta(3) integrin antagonists. Great efforts are being made to develop suitable tracers for different target structures. All of the major strategies focusing on the development of radiolabelled compounds for use with positron emission tomography are summarized in this review. However, because the most intensive work is concentrated on the development of radiolabelled RGD peptides for imaging alpha(v)beta(3) expression, which has successfully made its way from bench to bedside, these developments are especially emphasized.

Citing Articles

FN1 shapes the behavior of papillary thyroid carcinoma through alternative splicing of EDB region.

Liu M, Chen P, Wei B, Tan H, Zhao Y, Ai L Sci Rep. 2025; 15(1):327.

PMID: 39747903 PMC: 11695688. DOI: 10.1038/s41598-024-83369-5.

Concomitant [F]F-FAZA and [F]F-FDG Imaging of Gynecological Cancer Xenografts: Insight into Tumor Hypoxia.

Kepes Z, Hegedus E, Sass T, Csikos C, Szabo J, Szugyiczki V In Vivo. 2024; 38(2):574-586.

PMID: 38418132 PMC: 10905447. DOI: 10.21873/invivo.13476.

VEGF-delivering PEG hydrogels promote vascularization in the porcine subcutaneous space.

Quizon M, Deppen J, Barber G, Kalelkar P, Coronel M, Levit R J Biomed Mater Res A. 2024; 112(6):866-880.

PMID: 38189109 PMC: 10984793. DOI: 10.1002/jbm.a.37666.

The role of clinical imaging in oncology drug development: progress and new challenges.

Murphy P, Galette P, Van der Aart J, Janiczek R, Patel N, Brown A Br J Radiol. 2023; 96(1150):20211126.

PMID: 37393537 PMC: 10546429. DOI: 10.1259/bjr.20211126.

In Vivo Anchoring Bis-Pyrene Probe for Molecular Imaging of Early Gastric Cancer by Endoscopic Techniques.

Luo Q, Fan C, Ying W, Peng X, Hu Y, Luan Z Adv Sci (Weinh). 2022; 10(4):e2203918.

PMID: 36437107 PMC: 9896057. DOI: 10.1002/advs.202203918.

References

Rodriguez-Porcel M, Cai W, Gheysens O, Willmann J, Chen K, Wang H . Imaging of VEGF receptor in a rat myocardial infarction model using PET. J Nucl Med. 2008; 49(4):667-73. PMC: 2853914. DOI: 10.2967/jnumed.107.040576. View

Curran S, Murray G . Matrix metalloproteinases: molecular aspects of their roles in tumour invasion and metastasis. Eur J Cancer. 2000; 36(13 Spec No):1621-30. DOI: 10.1016/s0959-8049(00)00156-8. View

Eliceiri B, Cheresh D . Role of alpha v integrins during angiogenesis. Cancer J. 2000; 6 Suppl 3:S245-9. View

Creamer D, Sullivan D, Bicknell R, Barker J . Angiogenesis in psoriasis. Angiogenesis. 2003; 5(4):231-6. DOI: 10.1023/a:1024515517623. View

Haubner R, Wester H, Burkhart F, Senekowitsch-Schmidtke R, Weber W, Goodman S . Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics. J Nucl Med. 2001; 42(2):326-36. View

Niu G, Chen X . PET Imaging of Angiogenesis. PET Clin. 2010; 4(1):17-38. PMC: 2753532. DOI: 10.1016/j.cpet.2009.04.011. View

Santimaria M, Moscatelli G, Viale G, Giovannoni L, Neri G, Viti F . Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer. Clin Cancer Res. 2003; 9(2):571-9. View

Li S, Peck-Radosavljevic M, Koller E, Koller F, Kaserer K, Kreil A . Characterization of (123)I-vascular endothelial growth factor-binding sites expressed on human tumour cells: possible implication for tumour scintigraphy. Int J Cancer. 2001; 91(6):789-96. DOI: 10.1002/1097-0215(200002)9999:9999<::aid-ijc1126>3.0.co;2-k. View

Nguyen M, Arkell J, Jackson C . Human endothelial gelatinases and angiogenesis. Int J Biochem Cell Biol. 2001; 33(10):960-70. DOI: 10.1016/s1357-2725(01)00007-3. View

10.

Wu Z, Li Z, Cai W, He L, Chin F, Li F . 18F-labeled mini-PEG spacered RGD dimer (18F-FPRGD2): synthesis and microPET imaging of alphavbeta3 integrin expression. Eur J Nucl Med Mol Imaging. 2007; 34(11):1823-1831. PMC: 4167588. DOI: 10.1007/s00259-007-0427-0. View

11.

Wu Y, Zhang X, Xiong Z, Cheng Z, Fisher D, Liu S . microPET imaging of glioma integrin {alpha}v{beta}3 expression using (64)Cu-labeled tetrameric RGD peptide. J Nucl Med. 2005; 46(10):1707-18. View

12.

Brooks P, Montgomery A, Rosenfeld M, Reisfeld R, Hu T, Klier G . Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell. 1994; 79(7):1157-64. DOI: 10.1016/0092-8674(94)90007-8. View

13.

Yuan F, Chen Y, Dellian M, Safabakhsh N, Ferrara N, Jain R . Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc Natl Acad Sci U S A. 1996; 93(25):14765-70. PMC: 26210. DOI: 10.1073/pnas.93.25.14765. View

14.

Tarli L, Balza E, Viti F, Borsi L, Castellani P, Berndorff D . A high-affinity human antibody that targets tumoral blood vessels. Blood. 1999; 94(1):192-8. View

15.

Roodhart J, Langenberg M, Witteveen E, Voest E . The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway. Curr Clin Pharmacol. 2008; 3(2):132-43. DOI: 10.2174/157488408784293705. View

16.

Chen X, Park R, Tohme M, Shahinian A, Bading J, Conti P . MicroPET and autoradiographic imaging of breast cancer alpha v-integrin expression using 18F- and 64Cu-labeled RGD peptide. Bioconjug Chem. 2004; 15(1):41-9. DOI: 10.1021/bc0300403. View

17.

Foda H, Zucker S . Matrix metalloproteinases in cancer invasion, metastasis and angiogenesis. Drug Discov Today. 2001; 6(9):478-482. DOI: 10.1016/s1359-6446(01)01752-4. View

18.

Hammes H, Brownlee M, Jonczyk A, Sutter A, Preissner K . Subcutaneous injection of a cyclic peptide antagonist of vitronectin receptor-type integrins inhibits retinal neovascularization. Nat Med. 1996; 2(5):529-33. DOI: 10.1038/nm0596-529. View

19.

Vihinen P, Kahari V . Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets. Int J Cancer. 2002; 99(2):157-66. DOI: 10.1002/ijc.10329. View

20.

Zheng Q, Fei X, Liu X, Wang J, Sun H, Mock B . Synthesis and preliminary biological evaluation of MMP inhibitor radiotracers [11C]methyl-halo-CGS 27023A analogs, new potential PET breast cancer imaging agents. Nucl Med Biol. 2002; 29(7):761-70. DOI: 10.1016/s0969-8051(02)00338-4. View